First Trust Advisors’s Viking Therapeutics VKTX Stock Holding History

First Trust Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.44M	Buy	+105,570	New	+$3.39M	﹤0.01%	1669
2024 Q4	–	Sell	-12,283	Closed	-$778K	–	2648
2024 Q3	$778K	Buy	+12,283	New	+$721K	﹤0.01%	2074
2022 Q3	–	Sell	-102,755	Closed	-$297K	–	2615
2022 Q2	$297K	Sell	102,755 -4,173	-4%	-$10.3K	﹤0.01%	2305
2022 Q1	$321K	Sell	106,928 -6,022	-5%	-$21.6K	﹤0.01%	2360
2021 Q4	$520K	Buy	112,950 +14,014	+14%	+$78.5K	﹤0.01%	2279
2021 Q3	$621K	Buy	+98,936	New	+$611K	﹤0.01%	2212

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

First Trust Advisors's VKTX Position: Q1 2026 in Review

First Trust Advisors opened a new position in Viking Therapeutics (VKTX) in Q1 2026: 105,570 shares worth $3.44M. The stake represents ﹤0.01% of the portfolio and ranks #1669 among its holdings. This is a return to the name: First Trust Advisors previously reported a position in VKTX as recently as Q3 2024.

First Trust Advisors first reported a position in VKTX in Q3 2021 and has held it in 6 quarters since. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

First Trust Advisors held 105,570 shares of Viking Therapeutics worth $3.44M as of Q1 2026.
Viking Therapeutics was a new First Trust Advisors position in Q1 2026.
Viking Therapeutics made up ﹤0.01% of First Trust Advisors's portfolio in Q1 2026, its #1669 holding.
First Trust Advisors first reported a position in Viking Therapeutics in Q3 2021 and has held it in 6 quarters since.
410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on First Trust Advisors's 13F filing for Q1 2026, filed 13 May 2026.